The firm said it expects to file an investigational new drug application for the autologous CAR T-cell therapy TPST-2003 in the US by the end of the year.
NEW YORK – Cbio will begin a European Phase I/II trial of its autologous T-cell therapy novoleucel for patients with late-stage cervical cancer, with initial results expected by the end of the year.
The firm is hoping to outline a potential path to accelerated approval for SGT-003 as it gears up to launch a randomized, controlled Phase III trial.
NEW YORK – Multinational artificial intelligence-focused drug discovery and development firm Owkin has spun out a new standalone precision oncology testing company called Waiv, which raised $33 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results